Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

December 1, 2020

Study Completion Date

January 8, 2021

Conditions
COVID-19Virus DiseasesMacrophage Activation SyndromeCorona Virus Infection
Interventions
DRUG

Anakinra

In case of diagnosis of MAS treatment with anakinra

DRUG

Tocilizumab

In case of diagnosis of immune dysregulation treatment with tocilizumab

Trial Locations (17)

11144

Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens

11526

Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens

11527

1st Department of Pulmonary Medicine and Intensive Care Unit, Athens

Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens

12462

2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens

4th Department of Internal Medicine, Attikon University Hospital, Athens

16673

Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens

19600

"Intensive Care Unit, Latsio, Thriasio Elefsis General Hospital", Elefsina

26504

Department of Internal Medicine, Patras University Hospital, Pátrai

41221

"Intensive Care Unit, Koutlimbaneio & Triantafylleio Larissa General Hospital", Larissa

41334

Department of Internal Medicine, Larissa University Hospital, Larissa

45500

Intensive Care Unit, Ioannina University Hospital, Ioannina

54636

Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki

54 634

Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki

546 35

Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki

546 39

Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki

546 42

Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki

All Listed Sponsors
lead

Hellenic Institute for the Study of Sepsis

OTHER

NCT04339712 - Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction | Biotech Hunter | Biotech Hunter